- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04801017
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects
A Double Blind, Randomized, Placebo Controlled, Multi Center Study of OT-101 in Hospitalized COVID-19 Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double blind, placebo controlled study to evaluate the efficacy, safety and tolerability of OT-101+Artemisinin when used in combination with SoC in hospitalized subjects with severe COVID 19. Written informed consent must be obtained from all subjects or their legally authorized representative (LAR) during screening (up to Day 3 prior to dosing) and prior to study related procedures being performed. Following completion of all screening assessments and meeting of eligibility criteria, subjects will be enrolled and randomized on Day 1 to either receive OT-101+Artemisinin or placebo+Artemisinin in a 2:1 ratio for 7 days in combination with SoC therapy per local SoC policies, followed to Day 28.
Subjects: includes subjects with severe COVID 19 (WHO COVID 19 Clinical Improvement Ordinal Scale 5 - non-invasive ventilation or high flow oxygen, or 6 - intubation and mechanical ventilation) at screening.
Subjects will undergo assessment during hospitalization or could discontinue their treatment with OT 101 or placebo during the 7 day infusion period or any time later during the study. All subjects will be closely monitored for adverse events (AEs) from signing the informed consent form (ICF) for at least 21 days after the final dose of study treatment (until Day 28). Standard of care treatment may continue as clinically indicated (after the 7 day dosing completion) as per local institutional guidelines. If subjects are discharged after Day 7 (after completing dosing), post discharge assessments can be done either at home (home health visit) or at the site. For subjects who are discharged before Day 28 or who withdraw from the study early will have follow up phone calls or will be followed up at site or a home visit to collect safety data until End of Study on Day 28. On days of laboratory assessments, discharged subjects may have a home visit.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Federico Lerner, MD
- Phone Number: 54 (911) 2852.0457
- Email: federico@latinaba.com
Study Locations
-
-
-
Jardim, Brazil
- Praxis Pesquisa Medica S / S Ltda
-
Contact:
- Marcelo Bacci, MD
- Phone Number: +55 11 2759-8377
- Email: mrbacci@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospitalized adult male or non-pregnant, non-lactating female subjects (between 18 and 80 years), with SARS-CoV-2 (previously known as 2019-nCoV) infection that is documented by authorized diagnostic PCR test. A rapid PCR test could also be used. Confirmation that subject has COVID-19 within the last 2 weeks prior to randomization.
- Meeting WHO COVID 19 Clinical Improvement Ordinal Scale Criteria 5 (non-invasive mechanical ventilation or high-flow oxygen) or Criteria 6 (intubation and mechanical ventilation).
- O2 sat <= 93%
- Male subjects and female subjects of childbearing potential must agree to use protocol specified methods of contraception.
- Female subjects of childbearing potential and women of non childbearing potential (defined as at least 2 years postmenopausal or permanently sterilized women [bilateral tubal ligation, bilateral ovariectomy, or hysterectomy]) must have a negative serum pregnancy test at screening or pretreatment on Day 1.
- The subject or a LAR has provided written informed consent.
- The subject or the LAR is aware of the investigational nature of this study and willing to comply with protocol treatments, and other evaluations listed in the ICF.
Exclusion Criteria:
- Participation in any other clinical trial of an experimental treatment for COVID-19 or participation in another interventional clinical trial, including an expanded access trial.
- Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS CoV 2 infection <24 hours prior to study drug dosing except for remdesivir.
- Uncontrolled hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), unstable angina, congestive heart failure of any New York Respiratory Association classification, serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), or history of myocardial infarction within 12 months of enrollment.
- Hypotension requiring vasoactive peptides, such as dopamine, norepinephrine, epinephrine, or dobutamine.
- Renal function impairment (creatinine clearance [Cr. Cl.] <50 mL/min, based on Modification of Diet in Renal Disease calculation).
Liver function impairment
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 × upper limit of normal (ULN), or ALT/AST >3 × ULN plus total bilirubin >2 × ULN.
- Total bilirubin >1.5 × ULN, unless the subject has known Gilbert's syndrome.
- Platelet count <50 000/µL
- Multi-organ failure.
- Document active infection with a bacterial pathogen requiring parenteral systemic antibiotics.
- Bacterial or fungal sepsis.
- History of live vaccination within the last 4 weeks prior to study enrollment; subjects must not receive live, attenuated influenza vaccine (eg, FluMist) within 4 weeks before enrolment or at any time during the study.
- History of an allergic reaction or hypersensitivity to the study drug or any component of the study drug formulation.
- Anti-inflammatory treatments other than steroids (eg, complement inhibitor, anti-GM-CSF antibody, anti-IL6 antibody) ARE PROHIBITED. However, antiviral drugs (eg, remdesivir,), systemic corticosteroids, and non steroidal anti inflammatory drugs (NSAIDs) ARE ALLOWED.
- Presence of any uncontrolled concomitant illness, serious illness, medical conditions, or other medical history, including laboratory results, which, in the Investigator's opinion, would be likely to interfere with their participation in the study.
- Major surgical procedure within 4 weeks prior to screening or anticipation of need for major surgical procedure during the course of the study.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to screening
- History of organ allograft.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OT-101 + Artemisinin + Standard of Care
OT-101 - Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days. Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral |
TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
Other Names:
Herbal Supplement/ Purified extract from Artemisia
Other Names:
|
Placebo Comparator: Placebo + Artemisinin + Standard of Care
Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral
|
Herbal Supplement/ Purified extract from Artemisia
Other Names:
0.9% sodium chloride injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of subjects with clinical improvement score measured by an 8-point WHO COVID-19 Clinical Improvement Ordinal Scale as assessed by the odds ratio (OR) at Day 14.
Time Frame: at Day 14
|
Clinical improvement is defined as • A score decrease to categories 1, 2, 3, or 4. |
at Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The OR at Days 7, 21, and 28 based on the clinical improvement score (as measured by an 8 point WHO COVID 19 Clinical Improvement Ordinal Scale).
Time Frame: at Day 7, 21, 28
|
Clinical improvement defined as per primary endpoint.
|
at Day 7, 21, 28
|
The OR at Days 7, 14, 21, and 28 of a decrease of at least 1, 2, 3, and 4 points in subjects with severe COVID 19.
Time Frame: at Day 7, 14, 21, 28
|
at Day 7, 14, 21, 28
|
|
Time to at least 2 point improvement from baseline on Days 7, 14, 21, and 28 in subjects with severe COVID 19.
Time Frame: at Day 7, 14, 21, 28
|
at Day 7, 14, 21, 28
|
|
Worsening (increase in clinical improvement score) of at least '1' score on Days 7, 14, 21, and 28.
Time Frame: at Day 7, 14, 21, 28
|
at Day 7, 14, 21, 28
|
|
Mortality by Days 7, 14, 21, and 28.
Time Frame: up to Day 28
|
up to Day 28
|
|
Duration of supplemental oxygen/ventilator support by Days 7, 14, 21, and 28.
Time Frame: up to Day 28
|
up to Day 28
|
|
Duration of intensive care unit stay by Days 7, 14, 21, and 28.
Time Frame: up to Day 28
|
up to Day 28
|
|
Duration of hospitalization by Days 7, 14, 21, and 28.
Time Frame: up to Day 28
|
up to Day 28
|
|
Ventilator free days by Day 14 and Day 28.
Time Frame: up to Day 28
|
up to Day 28
|
|
Days on ventilation.
Time Frame: up to Day 28
|
up to Day 28
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of AEs and treatment-emergent AEs (TEAEs).
Time Frame: up to 28 days
|
up to 28 days
|
Adverse events leading to premature discontinuation of the study treatment.
Time Frame: up to 28 days
|
up to 28 days
|
Changes in radiology tests (chest X-ray or chest computed tomography [CT]) from baseline.
Time Frame: up to 28 days
|
up to 28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Vuong Trieu, PhD, Oncotelic Inc.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Anti-Infective Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Artemisinins
- Artemisinin
- Trabedersen
Other Study ID Numbers
- C002 2020 01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on OT-101
-
Oncotelic Inc.Not yet recruitingPancreatic Ductal Adenocarcinoma
-
The University of Texas Medical Branch, GalvestonUniversity of Texas Southwestern Medical Center; United States Army Institute... and other collaboratorsCompletedMuscle Weakness | Muscle; Fatigue, Heart | Late Effect of Burn | Burn RehabilitationUnited States
-
Seoul National University Bundang HospitalActive, not recruitingStroke | HemiplegiaKorea, Republic of
-
Oncotartis, Inc.UnknownLymphoma | Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, T-Cell | Lymphoma, Hodgkin | Lymphoma, Peripheral T-CellUnited States
-
Henry Ford Health SystemHenry Ford HospitalCompletedTranscatheter Aortic Valve ImplantationUnited States
-
Chang Gung Memorial HospitalCompleted
-
Johns Hopkins UniversityEnrolling by invitationSleep | Depression, Anxiety | Physical Inactivity | Psychiatric HospitalizationUnited States
-
Virginia Commonwealth UniversityCompletedMotor Coordination or Function; Developmental DisorderUnited States
-
The Methodist Hospital Research InstituteNot yet recruiting